Access cutting-edge myelofibrosis treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access myelofibrosis specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related myelofibrosis treatment provided free
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thromb
Sponsor: Swedish Orphan Biovitrum
Check if you qualify for this myelofibrosis clinical trial in Phoenix, AZ
If you're searching for myelofibrosis treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.